Comparative Efficacy of Mepolizumab and Dupilumab in Eosinophilic COPD: Insights from a Matching-Adjusted Indirect Treatment Comparison

Highlight

• No statistically significant difference between mepolizumab and dupilumab in reducing moderate/severe exacerbations in eosinophilic COPD.
• Both treatments showed comparable improvements in health-related quality of life as measured by SGRQ-C.
• Matching-adjusted indirect comparison (MAIC) methodology allowed adjustment for population differences across clinical trials.
• Findings support the interchangeable clinical utility of these monoclonal antibodies targeting type 2 inflammation in COPD patients with high eosinophil counts.

Study Background